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Summary
Drug poisoning is a common cause for attendance in the
emergency department. Several toxicology centres suggest
performing urinary drug screens, even though they rarely
influence patient management.
STUDY OBJECTIVES: Measuring the impact on patient
management, in a University Emergency Department with
approximately 40 000 admissions annually, of a rapid ur-
inary drug screening test using specifically focused indic-
ations. Drug screening was restricted to patients having a
first psychotic episode or cases demonstrating respiratory
failure, coma, seizures, a sympathomimetic toxidrome,
severe opiate overdose necessitating naloxone, hypoten-
sion, ventricular arrhythmia, acquired long QT or QRS
>100 ms, and high-degree heart block.
METHODS: Retrospective analysis of Triage® TOX drug
screen tests performed between September 2009 and
November 2011, and between January 2013 and March
2014.
RESULTS: A total of 262 patients were included, mean age
35 ± 14.6 (standard deviation) years, 63% men; 29% pois-
oning with alcohol, and 2.3% deaths. Indications for test-
ing were as follows: 34% were first psychotic episodes;
20% had acute respiratory failure; 16% coma; 8% seizures;
8% sympathomimetic toxidromes; 7% severe opioid
toxidromes; 4% hypotension; 3% ventricular arrhythmias
or acquired long QT intervals on electrocardiogram. A total
of 78% of the tests were positive (median two substances,
maximum five). The test resulted in drug-specific therapy
in 6.1%, drug specific diagnostic tests in 13.3 %, prolonged
monitoring in 10.7% of methadone-positive tests, and psy-
chiatric admission in 4.2%. Overall, 34.3% tests influenced
patient management.
CONCLUSIONS: In contrast to previous studies showing
modest effects of toxicological testing, restricted use of
rapid urinary drug testing increases the impact on manage-
ment of suspected overdose patients in the ED.
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Introduction
Drug poisoning due to psychotropic medication or illegal
drug use is frequent in emergency departments (EDs). In
most cases, supportive treatment alone is sufficient without
the need for specific drug identification. However, severe
intoxication with unknown substances is considered an in-
dication for urinary drug screening by several toxicology
centres, despite very limited influence on therapeutic de-
cisions [1].
A thorough history and exploration of the environment by
relatives, friends, witnesses and paramedics is mandatory,
but the reliability of information provided and the person-
al history in intoxicated and/or psychiatric ED patients are
often limited [2, 3]. In these situations, there is an un-
met need for precise information concerning potential drug
poisoning. Consequently, laboratory screening of suscept-
ible patients is widely utilised, including qualitative urin-
ary drug screening tests providing rapid results. Other more
expensive methods such as liquid or gas chromatography
and mass spectrometry are rarely used. Guidelines from
several toxicology centres recommend testing in severe
drug poisoning where the responsible agents are unknown
[4]; however, in adult psychiatric patients with stable vital
signs, routine testing is discouraged by the American Col-
lege of Emergency Physicians (ACEP) guidelines [5]. Data
on the impact of toxicology tests on patient management
are, however, scarce and have shown relatively little im-
pact, if any [1, 6–11]. To date, no study done amongst non-
trauma emergency patients using focused indications for
drug screening has been published and no such clinical
trial is currently under way (www.clinicaltrials.gov;
16.08.2015).
The purpose of this study was to investigate whether fo-
cused use of rapid drug screening tests has an impact on
treatment decisions.
Patients and methods
This monocentric study was performed at the ED of our
university hospital, which serves as a primary care centre
for our city, as well as a tertiary care centre for our and
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neighbouring cantons. The ED admits around 40 000 pa-
tients every year.
We performed a retrospective analysis of the patients’ med-
ical records for all 262 rapid urinary drug screening tests
performed between September 2009 and November 2011,
and between January 2013 and March 2014 for ED patients
over 18 years of age. Data for the intervening 113 tests per-
formed between December 2011 and December 2012 were
unavailable, owing to the loss of the laboratory database
during this period. However, our rules for requesting drug
screening tests and outlining drug poisoning treatment re-
mained unchanged during this period. In our institution,
we had developed certain clinical criteria for screening pa-
tients, aimed at improving patient selection and so enhan-
cing the positive yield of toxicology testing. We used the
prediction criteria for severe overdoses requiring intensive
care defined by Brett et al. [12], in addition to other criteria
(table 1).
Once hypoglycaemia was excluded, attending physicians
were obliged to complete a specific form to order the test,
noting the presence of at least one of the mandatory criteria
and also noting the expected impact of the test result on
patient management from the following list: (1) treatment
decision, (2) diagnostic decision, (3) duration of monitor-
ing (i.e. methadone), (4) patient admission (i.e., transfer to
a psychiatric ward). Physicians were informed that the test
detected therapeutic as well as toxic levels of paracetamol
and that treatment decisions related to paracetamol should
thus be based on quantitative tests [13].
We used the Triage® TOX drug screen (Biosite Inc., San
Diego, CA, USA), a fluorescence immunoassay using 11
distinct monoclonal antibodies for the simultaneous qual-
itative determination of paracetamol, amphetamines,
methamphetamines, barbiturates, benzodiazepines, co-
caine, methadone, opioids, phencyclidine, cannabinoids or
tetrahydrocannabinoids and tricyclic antidepressants. Test
results were interpreted by the Triage MeterPro from Bios-
ite Inc., an automatic scanner minimising the possibility of
ambiguous results. Threshold concentrations, and sensitiv-
ity and specificity data for each molecule are displayed in
the appendix.
Based on a retrospective analysis of medical records, we
considered the following decisions as triggered by test res-
ults: (1) administration of a specific antidote (N-acetyl-
cysteine, flumazenil or naloxone), (2) administration of
any other considered drug-specific treatment, (3) comple-
tion of further drug-specific diagnostic tests, (4) change
in a patient’s admission orientation if the indication was a
first psychotic episode (i.e. admission to a general ward if
the test was positive vs psychiatric ward if negative), or
(5) continuous electrocardiogram monitoring in the ED for
methadone-positive cases. Drug-specific treatments were,
for example, administration of N-acetylcysteine if testing
for paracetamol was positive and then confirmed by quant-
itative analysis, bicarbonate in tricyclic antidepressant pos-
itive patients, naloxone in opioid, or flumazenil in benzo-
diazepine positive patients, and any decision prior to test
results was interpreted as not test-triggered. (An overview
of the drug-related criteria which were used is shown in
table 2.)
Medical decisions taken only after test results were avail-
able were interpreted as being based on the test results. The
study protocol was approved by our local ethics committee.
Results
Between September 2009 and November 2011, and
between January 2013 and March 2014, 262 urine toxic-
ology screening tests were performed. The mean patient
age was 35 years ± 14.6 (standard deviation [SD]) (range
16–88 years); 63% were men; 76 patients (29%) had con-
comitant poisoning with alcohol (blood alcohol level >11
mmol/l). Six patients (2.3%) died, one of a fatal overdose
(rapid test positive for benzodiazepines, opiates, methad-
one, cannabinoids), one of an intracranial haemorrhage at-
tributed to cocaine abuse despite a negative urine screening
test, one of a diphenhydramine overdose with a positive
Table 1: Restrictive indications for toxicological screening in the
emergency department for suspected overdose.
Acute respiratory failure (pCO2 45–80 mm Hg or emergency
intubation)
Seizures
Coma / Glasgow coma scale score ≤8
Systolic hypotension (<80 mm Hg)
Acquired QRS enlargement (QRS >100 ms)
QT interval prolongation (QT >480 ms)
Severe ventricular arrhythmia (ventricular tachycardia or flutter, or
torsades de pointes)
New ≥2nd degree heart block
Opioid toxidrome treated with naloxone
Sympathomimetic toxidrome
First psychotic episode
Table 2: Drug specific tests, disposition or therapeutic decisions based on a positive result of the urine drug screening.
Screened substance Other tests / disposition Therapeutic decision
Paracetamol Serum paracetamol concentration
Liver enzymes
Administration of N-acetylcysteine
(Met)amphetamines Creatine kinase
Liver enzymes
Administration of nitrates, NaCl 3% (in the case of
hyponatraemia), aggressive hydration, bicarbonate
Benzodiazepines Administration of flumazenil
Cocaine Creatine kinase, troponin, computed tomography
if aortic dissection or subarachnoid haemorrhage
suspected
Administration of nitrates, acetylsalicylic acid,
nitroprusside, and/or phentolamine.
No beta-blockers.
Methadone/opiates Prolonged monitoring if methadone positive Administration of naloxone
Tricyclic antidepressants Electrocardiogram Administration of bicarbonate
All Somatic hospitalisation if first psychotic episode
and test positive / transfer to psychiatry if
negative
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benzodiazepine test, one of a fatal subarachnoid haemor-
rhage with a negative drug screen, one of multiple stab
wounds with a negative drug screen, one a recipient of a
liver transplant with positive tests for paracetamol and tri-
cyclic antidepressants.
Test indications (fig. 1) were a first psychotic episode in
126 (34%), acute respiratory failure in 75 (20%), coma in
59 (16%), seizures in 29 (8%), severe opioid toxidrome in
26 (7%), sympathomimetic toxidrome in 28 (8%), hypoten-
sion in 15 (4%), and severe ventricular arrhythmia or ac-
quired long QT syndrome in 11 (3%). Many patients had
more than one test indication leading to a total number of
369 reported indications in 262 patients.
204 urine tests (78%) were positive, including 92 (35%) for
more than one drug. Altogether, 348 substances were de-
tected, with a median of two per patient and a maximum of
five (fig. 2). None of the 262 patients was tested positive
for phencyclidine.
The tests resulted in prescription of a drug-specific therapy
in 16 (6.1%) cases, in drug-specific additional diagnostic
Figure 1
Indications for urinary drug screening (n = 369) in 262 patients.
Arrhythmia or long QT = QT prolongation >480 ms, or ventricular
tachycardia or flutter, or torsade de pointes tachycardia;
Hypotension = systolic hypotension (<80 mm Hg); Opiate toxidrome
= if requiring antagonist administration; Psychosis = first psychotic
episode; Resp failure = acute respiratory failure (pCO2 45-80
mm Hg or emergency intubation); Sympathomimetic = clinical signs
of sympathomimetic toxicity
Figure 2
Spectrum of substances detected with the Triage® TOX screen
(204 positive urine samples with 348 substances detected).
AMP = amphetamines; BAR = barbiturates; BZO =
benzodiazepines; COC = cocaine; MAMP = metamphetamines;
MTD = methadone; OPI = opiates; PAR = paracetamol; TCA =
tricyclic antidepressants; THC = tetrahydrocannabinoids
tests in 35 (13.3%), in prolongation of monitoring in 28 pa-
tients (10.7%) with tests positive for methadone, and in the
patient’s psychiatry admission in 11 (4.2%). Altogether 90
patients (34.3%) had their management influenced by the
rapid urine drug screen.
Discussion
Our study shows that focused indications for urine drug
testing in ED patients with suspected drug poisoning does
change patient management in more than one in three pa-
tients. Our results confirm results of Fabbri et al., who repor-
ted that focused toxicological testing increases interobserver
agreement on patient placement and management and leads
to reduced admission rates [14]. On the other hand, unres-
tricted use of urinary drug testing influenced patient man-
agement in only 4.4% [6] or not at all [1]. Equally, in an
urban psychiatric emergency service, routine drug screen-
ing tests had no effect on patient management [7]. Similarly,
in paediatric overdose patients, one study showed only 3%
treatment changes [8], while others did not report any impact
on treatment and/or placement [9, 10].
Consequently, better patient selection appears to be the
key determinant in terms of the usefulness of urinary drug
screening tests. A Swiss study on 74 patients concluded
that testing was justified in only 28%, but the authors did
not detail the exact impact on treatment decisions [11]. In
trauma patients, a clinical decision rule selecting patients
for screening based on age, hour of the day, day of the
week and type of trauma was suggested. This rule reduced
screening by 48%, missing only 5% of true overdoses [15].
However this rule has not yet been prospectively validated.
In other studies, the yield of screening using a comprehens-
ive test detecting 900 substances, ranged from 18% in un-
selected emergency patients [16] to 64% [17], much lower
than the 78% in our highly selected patients. This higher
proportion of positive tests underlines the usefulness of in-
sisting on focused indications for testing, especially given
the costs generated by these tests (CHF 155.60 each).
Figure 3
Impact of test results on clinical decisions (in %, n = 90)
consecutive to the detection of substances with the Triage® TOX
drug screen (n = 262 tests). Toxin-specific administration of
naloxone, flumazenil or N-acetycysteine or other drug-specific
treatments after test results.
Diagnostic tests = drug-related diagnostic tests ordered after test
result; disposition = psychiatry transfer influenced by negative
screening / somatic transfer if positive; prolonged monitoring =
longer monitoring when methadone positive
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Rapid urinary drug screening tests, however, have their spe-
cific limitations; they are mostly immunoassays, recognising
parts of the molecular structure of a substance or its meta-
bolites, and were developed originally to screen employees
for substance abuse. Their cut-off limits are not adapted to
identify overdoses and do not provide quantitative inform-
ation [18]. Moreover, there are many reports of false pos-
itive and false negative tests, thus limiting the accuracy of
these tests [19]. On the other hand, rapid tests alone have
the potential to influence specific management of patients
presenting with drug-poisoning in the ED. However, most
urinary toxicology screening tests only detect a limited num-
ber of substances. Designer drugs are detected with highly
variable sensitivity. In our study, two patients died of drug
overdose, one because of the antihistamine diphenhydram-
ine, which is not detected by the test. A negative drug screen
can thus lead inexperienced physicians erroneously to ex-
clude an overdose. Positive drug screens indicate the pres-
ence of a substance, and do not confirm overdose, and must
be interpreted cautiously in the clinical context of the pa-
tient. Therefore, education about the specific characteristics
of each screening test is essential prior to their implementa-
tion. In our institution, there is clear notification on the test
order form for doctors concerning the limitations of the test.
As the test does not detect cholinergic and anticholinergic
drugs, which, furthermore, require supportive treatment, the
related toxidromes are not listed in the indications.
There are some limitations in our study: it was a mono-
centric and retrospective analysis of a highly selected pa-
tient population, which corresponds to a small percentage
of 40 000 annual ED patients in our institution.
In-patient placement was sometimes incompletely docu-
mented. Other diagnostic tests may also have been con-
ducted in parallel with the rapid toxicology screening test,
especially timing of blood tests for parameters considered
routine like creatine kinase or liver enzymes, and inter-
ference with the results of these other tests cannot be ex-
cluded, making our assumptions on clinical decision-mak-
ing possibly flawed. Our study addressed the potential
overuse of a rapid screening test, but its retrospective
design prevented the documentation of underuse. We ob-
served longer monitoring periods for methadone-positive
patients and concluded the prolongation of monitoring to
be a decision triggered by the test.
In conclusion, our study shows that the restrictive use of a
rapid drug screening test increases its efficiency in relation
to a change in the management of severe drug poisoning.
Our focused policy has the potential both of improving pa-
tient management, and reducing costs generated by unneces-
sary laboratory tests or inappropriate admission. However,
our policy needs to be validated prospectively in other set-
tings. With the proviso that supportive care must continue to
be based on the suspected cause of poisoning based on pa-
tient and witness histories, toxidromes, and clinical findings,
qualitative tests have a place in specific selected cases.
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Appendix
Threshold concentrations for a presumptive positive result with the Triage® TOX drug screen.
Drug class screened Calibrated compound Threshold concentration of calibrated compound
Paracetamol Paracetamol 5 μg/ml
Amphetamines d-Amphetamine 1000 ng/ml
Metamphetamines d-Methamphetamine 1000 ng/ml
Barbiturates Pentobarbital 300 ng/ml
Benzodiazepines Estazolam 300 ng/ml
Cocaine Benzoylecgonine 300 ng/ml
Methadone d/l-Methadone 300 ng/ml
Opiates Morphine 300 ng/ml
Phencyclidine Phencyclidine 25 ng/ml
Cannabinoids/tetrahydrocannabinoids 11-nor-9 carboxy-Δ9-THC 50 ng/ml
Tricyclic antidepressants Desipramine 1000 ng/ml
Sensitivity / Specificity for cut-off concentrations of Triage® TOX drug screen for each detected compound as compared with gas chromatography-mass spectrometry (GC/
MS), except high-performance liquid chromatography (HPLC) for tricyclic antidepressants (data provided from manufacturer’s brochure).
Drug class screened Sensitivity (%) Specificity (%)
Paracetamol 100 95
Amphetamines 95 98.4
Metamphetamines 97.5 96.8
Barbiturates 100 81.4
Benzodiazepines 97.9 97.3
Cocaine 91.9 100
Methadone 100 84.2
Opiates 100 90.7
Phencyclidine 100 97.6
Cannabinoids/tetrahydrocannabinoids 100 84.4
Tricyclic antidepressants 92.1 90.2
Sensitivity / Specificity for cut-off concentrations of Triage® TOX drug screen for each detected compound as compared with Microgenics cloned enzyme donor
immunoassay (CEDIA) or DRI (tricyclic antidepressants) methods on a Roche Hitachi 917 (data calculated from unpublished data, Scholer A. University Hospital Basel
2007, 50 urine samples). All discrepant results were confirmed by LCMS mass spectrometry (LCMSMS) (benzodiazepines, THC-carbonic acid), liquid chromatography-
mass spectrometry (LCMS) (opiates, cocaine plus metabolites, amphetamine class) and other immunoassays; acetaminophen on DADE Dimension or, if enough sample
material, HPLC (acetaminophen).
Drug class screened Sensitivity (%) Specificity (%)
Paracetamol 88.9 100
Amphetamines + metamphetamines 100 100
Barbiturates 100 100
Benzodiazepines 95.6 (100)* 100
Cocaine 100 100
Methadone 100 100
Opiates 100 100
Cannabinoids/tetrahydrocannabinoids 100 100
Tricyclic antidepressants 25 97.6
* Urine sample was negative as confirmed by chromatography resulting in sensitivity of Triage® TOX drug screen of 100%. Phenylcyclidine negative samples were not
further tested.
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Figures (large format)
Figure 1
Indications for urinary drug screening (n = 369) in 262 patients.
Arrhythmia or long QT = QT prolongation >480 ms, or ventricular tachycardia or flutter, or torsade de pointes tachycardia; Hypotension =
systolic hypotension (<80 mm Hg); Opiate toxidrome = if requiring antagonist administration; Psychosis = first psychotic episode; Resp failure =
acute respiratory failure (pCO2 45–80 mm Hg or emergency intubation); Sympathomimetic = clinical signs of sympathomimetic toxicity
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Figure 2
Spectrum of substances detected with the Triage® TOX screen (204 positive urine samples with 348 substances detected).
AMP = amphetamines; BAR = barbiturates; BZO = benzodiazepines; COC = cocaine; MAMP = metamphetamines; MTD = methadone; OPI =
opiates; PAR = paracetamol; TCA = tricyclic antidepressants; THC = tetrahydrocannabinoids
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Figure 3
Impact of test results on clinical decisions (in %, n = 90) consecutive to the detection of substances with the Triage® TOX drug screen (n = 262
tests). Toxin-specific administration of naloxone, flumazenil or N-acetycysteine or other drug-specific treatments after test results.
Diagnostic tests = drug-related diagnostic tests ordered after test result; disposition = psychiatry transfer influenced by negative screening /
somatic transfer if positive; prolonged monitoring = longer monitoring when methadone positive
Original article Swiss Med Wkly. 2015;145:w14242
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 8
